Library Learn Dosing The crew Community πŸ’¬ Join the Discord
Home / Library / Tesamorelin
Sourced profile GHRH analogue

Tesamorelin

A growth-hormone-releasing-hormone analogue that stands apart from most of this list: it has a real clinical evidence base and an FDA-approved use.

Read this first: this is educational information, not medical advice, and PepConnection does not sell peptides, supplies, or supplements.

Many compounds discussed here are sold as "research chemicals" and are not approved for human use outside of clinical trials. Laws vary by country, and nothing here is a recommendation to obtain or use anything. Talk to a qualified clinician about your own situation.

What it is

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Like CJC-1295 it works β€œupstream” β€” prompting the body's own GH release β€” but unlike most peptides discussed online, it has a documented clinical evidence base and an approved indication.

How it works

By acting on GHRH receptors, tesamorelin stimulates the pituitary to release growth hormone, which in turn raises IGF-1. In its approved use, this drives a reduction in visceral adipose tissue (the deep abdominal fat associated with metabolic risk).

Approved use & evidence

Tesamorelin is described as standing apart precisely because it has a documented clinical evidence base, an FDA-approved indication, and a well-understood mechanism. It was approved in 2010 (Egrifta) for HIV-associated lipodystrophy and is noted as the only FDA-approved peptide for visceral fat reduction. That's a much stronger footing than the research-chemical peptides elsewhere in this directory.

Safety

Because it raises GH and IGF-1, its effects and cautions track growth-hormone signaling β€” including potential joint aches, fluid retention, injection-site reactions, and effects on glucose metabolism that warrant monitoring. As an approved drug it comes with a defined label, contraindications, and monitoring guidance β€” another reason approved products differ from unsupervised use.

Regulatory status

FDA-approved for a specific indication (HIV-associated lipodystrophy); prescription-only. Any use outside that indication is off-label and should involve a clinician.

FAQ

Q How is it different from CJC-1295?

Both are GHRH-related and prompt GH release, but tesamorelin is an approved medication with trial evidence and a defined indication, whereas CJC-1295 is investigational and sold as a research chemical.

Q Is it a weight-loss drug?

Its approval is specifically for reducing visceral fat in HIV-associated lipodystrophy β€” not general weight loss. Off-label use is a clinician conversation.

Q Does it raise IGF-1?

Yes β€” by stimulating GH release, it raises IGF-1, which is part of both its effect and its monitoring considerations.

Sources

This profile summarizes the following. Follow the links to read the originals β€” and remember that summaries age, so check for newer information.

Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.

Keep reading